A group of Democratic senators are calling on Health and Human Services Secretary Robert F. Kennedy Jr. to keep a proposed ...

The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden administration that would have allowed Medicare and Medicaid beneficiaries ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the ...

The Trump administration said Friday that Medicare and Medicaid won’t expand coverage of popular anti-obesity drugs, ...

The Trump administration has decided against implementing a proposal for Medicare and Medicaid to cover weight loss drugs, ...

This decision is a blow for Eli Lilly and Novo Nordisk, who had both previously endorsed the proposed expansion.

Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.

The previous administration attempted to have Medicare Part D and Medicaid cover anti-obesity drugs under the Contract Year 2026 MA and Part D rule, which would have substantially increased access ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...